Skip to content
Search

Latest Stories

Ananya Panday to star opposite Vijay Deverakonda in Dharma Productions next?

Vijay Deverakonda is a star down South, and thanks to Arjun Reddy, the actor has become a household name. Now, he is all set to make his Bollywood debut with a film being directed by Puri Jagannadh and presented and co-produced by Karan Johar’s Dharma Productions.

There were reports that Janhvi Kapoor might be seen opposite Vijay in the film, but now, according to a tabloid, the makers have roped in Ananya Panday to play the female lead. A source stated that the makers were keen to rope in a young actress opposite Vijay in the film.


The source said, “Ananya is eager to work with Vijay and is expected to start shooting mid-March or in the first week of April.”

Well, we have to say that Ananya is on a roll. The actress made her Bollywood debut last year with Student Of The Year 2 and was also a part of the film Pati Patni Aur Woh.

Ananya will next be seen on the big screen in Khaali Peeli which also stars Ishaan Khatter. Apart from Khaali Peeli, Ananya will be seen in Shakun Batra’s next in which she will be sharing screen space with Deepika Padukone and Siddhant Chaturvedi. The actress also has one more film in her kitty which stars Siddhant Chaturvedi and Saif Ali Khan.

Talking about Vijay Deverakonda, the actor is gearing up for the release of his Telugu film World Famous Lover which is slated to release on 14th February 2020.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less